Business Model


- Game changer for unmet medical need.

- Science validated across multiple in vitro and in vivo models.

- Advanced from feasibility tests to drug development.

- Extensive world-wide patent portfolio.

- Pipeline of products in development.

- Ability to obtain non-dilutive funding.

- Ability to attract equity investment.

- Clearly defined regulatory process.


Allander focuses on cell-penetrating biologics



  • Han GW, Li AG, Liang YY, Owens P, He W, Lu S, Yoshimatsu Y, Wang D, tenDijke P, Lin X, Wang XJ (2006). Smad7-induced β-catenin degradation alters epidermal appendage development. Dev Cell, 11, 301-312 (Read here).
  • Han G, Li F, Ten Dijke P, Wang XJ (2011). Temporal smad7 transgene induction in mouse epidermis accelerates skin wound healing. Am J Pathol. 179:1768-79 (Read here).
  • Han G, Bian L, Li F, Cotrim A, Wang D, Lu JB, Deng Y, Bird G, Sowers A, Mitchell J, Gutkind JS, Zhao R, Raben D, ten Dijke P, Refaeli Y, Zhang QH, and Wang XJ (2013). Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med, 19: 421-428 (Read here). 
  • Luo J, Bian L, Blevins MA, Wang D, Liang C, Du D, Wu F, Holwerda B, Zhao R, Raben D, Zhou H, Young C, Wang XJ (2018). Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res. 2018 Sep 5. pii: clincanres.1081.2018. doi: 10.1158/1078-0432.CCR-18-1081. [Epub ahead of print]. (Read here). 
  • Li F, Bian L, Iriyama S, Jian Z, Fan B, Luo JJ, et al. Smad7 ameliorates TGFbeta-mediated skin inflammation and associated wound healing defects but not the susceptibility to experimental skin carcinogenesis. J Invest Dermatol. 2018. Epub  2018/11/14. doi: 10.1016/j.jid.2018.10.031. PubMed PMID: 30423327. (Read here)